TCTMD7 小时
HF Benefits Look Durable in Single-Arm Study of Coronary Sinus Shunt
The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.
rheumatologyadvisor14 小时
Sildenafil Shows Potential for Improving Cardiac Outcomes in Systemic Sclerosis
Sildenafil was effective for reducing diastolic dysfunction and altered ejection fraction among patients with SSc.
Heart Failure Deaths Are Increasing. New Treatments Could Help.
The deaths are also partly the result of medical successes: People are living longer, and more people are surviving heart ...
Pharmabiz3 天
Bayer seeks Japanese marketing approval for finerenone to treat adult patients with chronic ...
Bayer seeks Japanese marketing approval for finerenone to treat adult patients with chronic heart failure: Berlin Saturday, February 15, 2025, 14:00 Hrs [IST] Bayer announced the ...
Medscape5 天
Shunt System Still Improving HF Symptoms at 2 Years
A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...
First Participant Randomized in AskBio European Phase 2 Gene Therapy Trial for Congestive ...
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms GenePHIT is a clinical ...